BioAdaptives' Zeranovia Receives IRB Approval for Human Clinical Trial in Weight Management
Key Insights
BioAdaptives Inc. (search) has secured IRB approval to begin a human clinical trial for Zeranovia (search), its weight management (search) product, marking a significant step in its development.
The initial phase of the trial will focus on confirming appropriate dosing and identifying any potential new side effects associated with Zeranovia (search).
BioAdaptives emphasizes its commitment to providing high-quality, scientifically validated products, highlighting that less than 1% of nutraceuticals undergo human trials.
BioAdaptives Inc. (search) (OTC: BDPT) has announced the approval of a human clinical trial for its weight management (search) product, Zeranovia (search), by an Institutional Review Board (IRB). The trial, to be conducted in Las Vegas, Nevada, will assess the safety and efficacy of Zeranovia, a nutraceutical formulation aimed at providing a natural approach to weight management.
The initial phase of the clinical trial is designed to confirm the appropriate dosage and monitor for any unforeseen side effects. According to BioAdaptives, the response to participate in the trial has been strong, with the first phase's slots quickly filled. A subsequent stage will be opened to accommodate additional participants.
Commitment to Scientific Validation
James Keener, CEO of BioAdaptives, emphasized the company's dedication to scientific rigor, noting that less than 1% of nutraceuticals in the U.S. undergo human clinical trials, according to the National Institutes of Health's Office of Dietary Supplements (ODS). "We are committed to supplying the highest quality products with provable scientific results," Keener stated.
Zeranovia's Composition and Potential
Zeranovia (search) is formulated with a high-protein blend of vitamins, minerals, and five concentrated herbal supplements, including four adaptogens. BioAdaptives suggests that Zeranovia could potentially offer a natural alternative to synthetic weight management (search) treatments like GLP-1 (search) and GIP (search) receptor agonists.
Keener's team dedicated nearly a year to product development, including extensive laboratory work, before transitioning Zeranovia (search) to BioAdaptives. The company anticipates that the human clinical trials will reflect the positive results observed during the development phase.
About BioAdaptives Inc.
BioAdaptives Inc. (search) is positioned as a leader in the nutritional products industry, focusing on innovative solutions for quality of life, anti-aging, cell repair, and overall well-being. The company emphasizes research-driven and customer-focused practices to deliver scientifically advanced solutions.